What are the recommended pharmacologic treatments for allergic rhinitis in pediatric patients, including age‑appropriate dosing?

Pediatric Medications for Allergic Rhinitis

Intranasal corticosteroids are the most effective first-line treatment for pediatric allergic rhinitis when symptoms affect quality of life, with second-generation oral antihistamines recommended for mild disease or when sneezing and itching predominate 1, 2.

First-Line Treatment Selection

For Moderate-to-Severe Disease

• Start with intranasal corticosteroids (INCS) as monotherapy for children with nasal congestion, rhinorrhea, sneezing, and itching that impact daily functioning 1
• INCS are superior to oral antihistamines, leukotriene receptor antagonists (LTRAs), and even the combination of oral antihistamine plus LTRA 1
• All available INCS (fluticasone propionate, mometasone furoate, budesonide) show similar clinical efficacy regardless of differences in potency or binding affinity 1
• Growth suppression has NOT been demonstrated at recommended doses with fluticasone propionate, mometasone furoate, and budesonide in children with perennial allergic rhinitis 1

For Mild Disease or Rapid Relief

• Use second-generation oral antihistamines (cetirizine, desloratadine, fexofenadine, levocetirizine, loratadine) when sneezing and itching are the primary complaints 1, 2
• These agents have excellent safety profiles in children, unlike first-generation antihistamines which cause sedation and performance impairment 1
• Intranasal antihistamines (azelastine, olopatadine) provide rapid onset (within hours) and are equal or superior to oral antihistamines, particularly for nasal congestion 1, 2

Age-Specific Safety Considerations

Critical Safety Warning for Young Children

Avoid OTC cough and cold medications containing first-generation antihistamines and decongestants in children under 6 years of age 1. Between 1969-2006, there were 54 fatalities with decongestants and 69 with first-generation antihistamines in children ≤6 years, primarily from overdose errors 1.

Safe Options by Age

• Second-generation antihistamines are safe and well-tolerated in young children when used at appropriate doses 1
• Cetirizine: approved age ≥2 years (5 mg/day ages 2-5; 10 mg/day age ≥6) 2
• Loratadine: approved age ≥2 years (5 mg/day ages 2-5; 10 mg/day age ≥6) 2
• Desloratadine: approved age ≥2 years (1.25 mg/day ages 2-5; 2.5 mg/day ages 6-11; 5 mg/day age ≥12) 2
• Fexofenadine: approved age ≥2 years (30 mg twice daily ages 2-11; 60 mg twice daily or 180 mg/day age ≥12) 2

When Initial Treatment Fails

Step-Up Algorithm

1. If INCS alone provides inadequate control, add intranasal antihistamine rather than oral antihistamine 3, 4, 5

   • The combination of INCS plus intranasal antihistamine (e.g., fluticasone + azelastine) shows greater symptom reduction than either agent alone 3
   • Adding oral antihistamine to INCS does NOT provide clinically meaningful additional benefit in most patients 3, 6, 4

2. Consider LTRAs only as add-on therapy in children with concomitant asthma 1, 4

   • LTRAs show no significant efficacy difference compared to oral antihistamines alone 1
   • Not recommended as first-line monotherapy for allergic rhinitis 4, 5

Specific Medication Dosing

Intranasal Antihistamines (Age ≥6 years)

• Azelastine 0.1%: 1 spray per nostril twice daily (ages 6-11); 1-2 sprays twice daily (age ≥12) 2
• Azelastine 0.15%: 1 spray per nostril twice daily (ages 6-11); 1-2 sprays twice daily (age ≥12) 2
• Olopatadine 0.6%: 1 spray per nostril twice daily (ages 6-11); 2 sprays twice daily (age ≥12) 2
• Azelastine + fluticasone combination: 1 spray per nostril twice daily (age ≥12 only) 2

Common Side Effects

• Bitter taste (most common with intranasal antihistamines, 2-13%) 3, 2
• Somnolence rates are low (0.4-3%) and similar to placebo 2
• Epistaxis with INCS is minimal and similar to placebo 1

Critical Pitfalls to Avoid

1. Never use intranasal decongestants for more than 3 days due to risk of rhinitis medicamentosa 1
2. Do not combine oral antihistamine with oral decongestant in children under 4 years due to stimulatory effects (tachyarrhythmias, insomnia, hyperactivity) 1
3. Avoid intramuscular corticosteroids - they should be discouraged in favor of intranasal formulations 1
4. Do not assume all INCS have growth effects - only beclomethasone dipropionate at doses exceeding recommendations has shown this effect 1

Timing Considerations

• INCS onset of action: 3-12 hours, with full benefit taking days to weeks 1
• Intranasal antihistamines: rapid onset within hours, appropriate for PRN use 1
• For seasonal allergic rhinitis: initiate INCS 1-2 weeks before anticipated pollen season for optimal control 4